ivWatch Receives NIOSH Approval for blox Surgical N95 Respirators, Adding to the Short List of Domestic Medical-Use N95 Manufacturers and the Only Company to Produce in Virginia

N95 Designation from NIOSH Leads to New Authentic Supply of Surgical N95s that Continue to be in Shortage

News provided by

Nov 16, 2021, 11:05 ET

NEWPORT NEWS, Va., Nov. 16, 2021 /PRNewswire/ -- Today, ivWatch, LLC, a leading medical device manufacturer of biosensors that detect IV infiltration and extravasation events, received approval from the National Institute for Occupational Safety and Health (NIOSH), a part of the Centers for Disease Control and Prevention (CDC), to produce surgical N95 respirators. The new designation allows ivWatch to produce blox Surgical N95 Respirators, under approval number TC-84A-9379, at the company's Hampton Roads headquarters to help close the gap in the surgical N95 respirator shortage. Unlike industrial-use N95 respirators, surgical N95 respirators are designed and tested specifically for medical and healthcare use.

ivWatch manufactures blox Surgical N95 Respirators, under approval number TC-84A-9379, at the company’s Hampton Roads headquarters.

ivWatch worked from the beginning to develop a pinnacle surgical N95 respirator made in the USA, with locally sourced materials, and manufactured at the company's domestic FDA registered facility. BLX-9501 underwent extensive sourcing requirements and as-made performance testing to ensure the highest of quality and standards in compliance with 42 CFR 84. The company was awarded NIOSH designation following a year-long development and application process as well as third-party validation testing from Nelson Labs and Pacific Biolabs. ivWatch has an established Quality Management System (QMS) that has been globally certified to ISO 13485 under the MDSAP program since 2018. An effective QMS is a critical aspect to any reputable medical device organization.

"We are proud to be one of only a handful of U.S.-based, authentic manufacturers to receive surgical N95 respirator designation from NIOSH," said Gary Warren, President and CEO of ivWatch. "Our company's foundation in engineering and mathematics allowed us to leverage our biosensor machinery to effectively create a new safety solution that can play a major role in protecting our communities. Just like we put seatbelts on when we get into a car, we are entering a time where a call for better respirators as the standard for safety and protection is necessary for our hospital systems; our respirators should put counterfeit, inferior N95s in the rearview mirror."

The designation comes as countries, states, municipalities, hospitals, airlines, and retail stores across the globe are re-evaluating or, in some cases, re-establishing mask mandates. Some are even taking it one step further and banning subpar cloth masks. Hospitals in parts of the country are also continuously in need of valuable, authentic PPE as they reach ICU capacity or anticipate influxes of highly contagious patients.

"Our manufacturing, quality, and regulatory teams have been working rigorously with NIOSH – from concept to design to final production – to gain surgical N95 respirator approval. Considering we are two years into the COVID-19 pandemic, we're honored to be approved by NIOSH at a critical time where high-filtration respirators could be the catalyst in turning the tide against this lethal pandemic across the globe," said Jaclyn Lautz, PhD, Chief Operating Officer at ivWatch.

blox products are backed by the vQuality system, an interactive database designed to combat poor quality and counterfeit respirators that have flooded the market. vQuality exposes the inline testing performance data from each lot of respirators. The blox Surgical N95 Respirator was analytically tested to comply with industry standards. The need for reliable, authentic, comfortable, and affordable respirators for hospitals remains.

blox Surgical N95 Respirators are tested to ensure greater than 95% filtration efficiency¹ and are built for extended wear times with a comfortable, secure fit and a 360-degree seal. blox Surgical N95 Respirators meet CDC guidelines for tuberculosis exposure control and are fluid resistant – critical requirements for respirators approved for medical, surgical, and clinical environments.

In the research and development phase, blox's unique pleated design was specifically engineered and manufactured to pass hospital fit testing protocols. blox Surgical N95 Respirators were third-party tested by Nelson Labs. Performance test results include:

Synthetic blood penetration resistance up to 160mmHg per ASTM F1862
Inhalation resistance (complete respirator): 7.3 (mm H2O)
Exhalation resistance (complete respirator): 9.4 (mm H20)
Flammability rating: Class I per 16 CFR 1610

Customers can learn more and see detailed testing reports by visiting: blox.ivwatch.com/product.

To purchase blox high performance products, customers can buy direct at BloxDirect.com. blox Surgical N95 Respirators (BLX-9501) are also available in bulk orders and can be purchased by contacting [email protected].

¹Nelson Labs. "Sodium Chloride (NaCl) Aerosol Test Report" (Study Number 1404015-S01). April, 2021.

About blox & vQuality
blox is a product line of high-fidelity particulate filtration face masks and surgical N95 respirators backed by ivWatch, LLC that designs, manufactures, and supplies biosensor medical devices to hospitals and facilities worldwide. Seeking to fill a need swarmed by counterfeit and below average face masks and respirators, ivWatch leveraged its research and development expertise in the healthcare industry and its manufacturing prowess to create superior high quality particulate respirators verified by the vQuality seal and system. vQuality is the company's authentication platform that provides transparency about product performance data to customers in an easily accessible, simplified report, which underscores blox's superior performance. To learn more, visit blox.ivwatch.com.

About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.

SOURCE ivWatch, LLC